GlassScriptPhysician profile
Monarch Shah
NPI 1447806039
$1,799.67
in general payments reported to CMS, 2019-2025
28 companies · $701 in 2025
The $701 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,098 · 2025: $701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,722 · Education: $77.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,722.24 |
| Education | $77.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $167.40 | 2024-2025 | Velphoro, Velphoro |
| Otsuka America Pharmaceutical, INC. | $151.11 | 2024-2025 | Jynarque, Voyxact |
| Novartis Pharmaceuticals Corporation | $134.15 | 2024-2025 | |
| Akebia Therapeutics INC | $125.67 | 2024-2025 | Vafseo, Auryxia |
| Amgen INC. | $121.52 | 2024-2025 | Tavneos, Krystexxa |
| Shield Therapeutics INC | $108.49 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $90.05 | 2024-2025 | |
| Medtronic, INC. | $84.79 | 2024 | Ellipsys Vascular Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.32 | 2024-2025 | Jardiance |
| Veloxis Pharmaceuticals, INC. | $71.27 | 2024 | |
| Ardelyx, INC. | $68.36 | 2024 | Ibsrela |
| Travere Therapeutics, INC. | $67.87 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $61.16 | 2024 | Acthar |
| Ani Pharmaceuticals, INC. | $58.08 | 2025 | Purified Cortrophin Gel |
| Xeris Pharmaceuticals, INC. | $48.21 | 2024 | Keveyis |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $45.92 | 2024 | |
| Calliditas Therapeutics US INC. | $45.35 | 2024-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $41.71 | 2024 | Benlysta |
| Lilly USA, LLC | $30.26 | 2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $28.87 | 2024 | Farxiga |
| Vifor Pharma, INC. | $27.56 | 2025 | Veltassa |
| Mozarc Medical US LLC | $25.51 | 2024 | Argyle |
| Aurinia Pharma U.S., INC. | $24.90 | 2024 | Lupkynis |
| Takeda Pharmaceuticals U.S.A., INC. | $20.77 | 2024 | Gattex |
| Kyowa Kirin, INC. | $19.68 | 2024 | Crysvita |
| Biomerieux INC | $19.36 | 2024 | Vidas Nephrocheck |
| Argon Medical Devices, INC. | $18.75 | 2025 | Clot Management |
| Scpharmaceuticals INC. | $18.58 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monarch Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.